nkg2d [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

natural killer group 2 member D ligands

Zhang et al. presented recent preclinical and clinical studies targeting well-characterized [[glioblastoma]] [[antigen]]s, which include the [[IL13RA2]] and the [[epidermal growth factor receptor]]. Afterward, they turn their attention to alternative [[target]]s in [[glioblastoma]], including less-explored antigens such as B7-H3 ([[CD276]]), [[carbonic anhydrase 9]], and the [[GD2]] [[ganglioside]]. They also discuss additional target ligands, namely [[CD70]], and [[NKG2D]]. Finally, they present the possibilities afforded by novel CAR architectures. In particular, they examine the use of armored [[CAR]]s to improve the survival and proliferation of [[CAR]] [[T cell]]s. They conclude by discussing the advantages of tandem and [[synthetic Notch]] CARs when targeting multiple [[glioblastoma antigen]]s
((Zhang J, Siller-Farfán JA. Current and future perspectives of [[chimeric antigen receptor]]s against [[glioblastoma]]. Immunother Adv. 2022 Jun 1;2(1):ltac014. doi: 10.1093/immadv/ltac014. PMID: 36284838; PMCID: PMC9585667.)).